[Featured Stock] 'DND Pharmatech' Up 10% on Second Day of Listing
On the 2nd, DND Pharmatech, which entered the KOSDAQ market, showed strong performance in the early trading session.
As of 9:39 AM on the 3rd, DND Pharmatech is trading at 40,200 KRW, up 10.14% (3,700 KRW) from the previous trading day.
Founded in 2014, DND Pharmatech is a specialized company developing chronic disease treatments using GLP-1 peptide-based therapies. The company is developing multiple innovative GLP-1-based new drugs, focusing on oral obesity treatments (DD02S, DD03), injectable MASH treatments (DD01), and degenerative brain disease treatments (NLY01). Last year, the company reported consolidated sales of 18.7 billion KRW and an operating loss of 13.5 billion KRW.
Hot Picks Today
!["Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①](https://cwcontent.asiae.co.kr/asiaresize/93/2026051914165468840_1779167814.png)
"Rather Than Endure a 1.5 Million KRW Stipend, I'd Rather Earn 500 Million in the U.S." Top Talent from SNU and KAIST Are Leaving [Scientists Are Disappearing] ①
- "No Cure Available, Spread Accelerates... Already 105 Dead, American Infected"
- [Breaking] President Lee: "Korea and Japan Agree on the Need for Rapid Restoration of Peace and Stability in the Middle East"
- "Not Jealous of Winning the Lottery"... Entire Village Stunned as 200 Million Won Jackpot of Wild Ginseng Cluster Discovered at Jirisan
- "How Did an Employee Who Loved Samsung End Up Like This?"... Past Video of Samsung Electronics Union Chairman Resurfaces
In the demand forecast for institutional investors conducted from the 12th to the 18th of last month, DND Pharmatech recorded a competition rate of 848.5 to 1 and set the public offering price at 33,000 KRW, exceeding the expected price range of 22,000 to 26,000 KRW.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
